Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure
|
|
- Sharleen Harvey
- 5 years ago
- Views:
Transcription
1 Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Adrian F. Hernandez, MD On behalf of the ASCEND-HF Committees, Investigators and Study Coordinators
2 Disclosure Information Adrian F. Hernandez, MD ASCEND-HF Trial FINANCIAL DISCLOSURE: Trial Sponsor: Scios Inc Research funding from Johnson & Johnson Honorarium from Amgen, Corthera Full listing of disclosures at dcri.org UNLABELED or UNAPPROVED USE: None
3 Study organization Sponsor Scios Inc. Executive Committee Chair: Rob Califf Chris O Connor (Co-PI), Randy Starling (Co-PI) Paul Armstrong, Kenneth Dickstein, Michel Komajda, Barry Massie, John McMurray, Markku Nieminen, Jean Rouleau, Karl Swedberg, Vic Hasselblad Independent DSMB Chair: Sidney Goldstein Salim Yusuf, David DeMets, Milton Packer, John Kjekshus International Steering Committee Clinical Event Committee Chair: John McMurray ROW: Johnson & Johnson Global Clinical Operations Coordinating center: DCRI Adrian Hernandez, Craig Reist, Gretchen Heizer North America Academic Consortium: (DCRI, C5, Jefferson, Henry Ford, Canadian VIGOUR Centre) >800 Investigators and Study Coordinators at 398 Sites
4 Background Acute heart failure is a major health problem responsible for several million hospitalizations worldwide each year. Standard therapy has not changed since 1970s and includes diuretics and variable use of vasodilators or inotropes. In 2001, nesiritide was approved by the FDA to reduce PCWP and improve dyspnea, based on efficacy at 3 hrs. However, in 2005 two meta-analyses raised concerns regarding the risks of mortality and renal injury. Subsequently, an independent panel* was convened by Scios Inc and recommended that a clinical trial be conducted to definitively answer the question of nesiritide s safety and efficacy. *chaired by Eugene Braunwald
5 Design of ASCEND-HF: Guiding principles Independent framework Pragmatic trial model Focused Efficient study design Streamlined procedures Simple follow-up Permissive enrollment criteria for broad population Meaningful outcomes Standard of care per local practice ( real world )
6 % Subjects Co-Primary objectives To assess whether nesiritide vs placebo, in addition to standard care provides: Reduction in rate of HF rehospitalization or all-cause mortality through Day 30 Significant improvement in self-assessed dyspnea at 6 or 24 hrs using 7-point Likert scale Markedly Better Moderately Better Minimally Better No Change Minimally Worse Moderately Worse Markedly Worse
7 Secondary and safety objectives Secondary endpoints: Overall well-being at 6 and 24 hours Persistent or worsening HF and all-cause mortality from randomization through discharge Number of days alive and outside of the hospital Cardiovascular rehospitalization and cardiovascular mortality Safety endpoints: All cause mortality Renal: 25% decrease in egfr at any time from study drug initiation through Day 30 Hypotension: As reported by investigator as symptomatic or asymptomatic
8 Study design and drug procedures Nesiritide Acute HF < 24 hrs from IV RX hrs Rx Placebo Co-primary endpoint: Dyspnea relief at 6 and 24 hrs Co-primary endpoint: 30-day death or HF rehosp All-cause mortality at 180 days Double blind placebo controlled IV bolus (loading dose) of 2 µg/kg nesiritide or placebo Investigator s discretion for bolus Followed by continuous IV infusion of nesiritide 0.01 µg/kg/min or placebo for up to 7 days Usual care per investigators including diuretics and/or other therapies as needed Duration of treatment per investigator based on clinical improvement
9 Inclusion and exclusion criteria Key inclusion criteria Hospitalized for ADHF <24 hrs from IV treatment Dyspnea at rest or with minimal activity 1 clinical sign: Respiratory rate 20 breaths per min Rales >1/3 bases 1 objective measure: CXR with pulmonary edema BNP 400 pg/ml or NT-proBNP 1000 pg/ml Prior EF <40% within 12 months PCWP > 20 mmhg Key exclusion criteria Hypotension at baseline (SBP <100 mm Hg or SBP<110 mm Hg with IV vasodilator) Significant lung disease that could interfere with interpretation of dyspnea Acute coronary syndrome Severe anemia or active bleeding Treatment with levosimendan or milrinone Unstable doses of IV vasoactive medication within 3 hours
10 Statistical methods Study population: modified intention-to-treat based on receiving study drug Primary analysis: Co-primary endpoints tested using Bonferroni approach Composite of HF rehospitalization and all-cause mortality tested at significance level Dyspnea tested at level using Hochberg method: Significant if both 6- and 24-hr assessment P values 0.005; or If either 6- or 24-hr assessment P values Sample size determination: Based on composite endpoint: 89% power with 7000 patients using chi-square test, assuming a placebo event rate of 14% and a relative risk reduction of 18.6%
11 Enrollment 7141 patients 30 Countries & 398 Sites Western Europe = 7% 35 sites North America = 45% 214 sites Latin America = 9% 39 sites Central Europe = 14% 48 sites Asia-Pacific = 25% 62 sites >800 Investigators and Study Coordinators
12 Study population Randomized (n=7141) Placebo (n=3577) Did not receive study drug (n=66) Hypotension (n=28) Exclusion criteria (n=8) Physician decision (n=6) Participant withdrew consent (n=14) Other reason (n=10) Nesiritide (n=3564) Did not receive study drug (n=68) Hypotension (n=26) Exclusion criteria identified (n=9) Physician decision (n=6) Participant withdrew consent (n=16) Other reason (n=11) Placebo MITT=3511 Nesiritide MITT=3496
13 Baseline characteristics Placebo (n=3511) Nesiritide (n=3496) Age (yrs) 67 (56, 76) 67 (56, 76) Female (%) Black or African American Systolic Blood Pressure (mmhg) 124 (110, 140) 123 (110, 140) Heart rate (beats/min) 82 (72, 95) 82 (72, 95) Respiratory rate (breaths/min) 24 (21,26) 23 (21, 26) Medical History (%) Ischemic heart disease Hypertension Atrial fibrillation Chronic respiratory disease Diabetes Continuous variables as median (IQR 25 th, 75 th ); MITT population
14 Baseline characteristics Labs/Studies Placebo (n=3511) Nesiritide (n=3496) LVEF <40% within 12 mths (%) BNP (pg/ml) 989 (543, 1782) NT pro-bnp (pg/ml) 4461 (2123, 9217) Creatinine (mg/dl) 1.2 (1.0, 1.6) 994 (544, 1925) 4508 (2076, 9174) 1.2 (1.0, 1.5) Pre-randomization treatment (%) Loop diuretics Inotropes Vasodilators Continuous variables as median (IQR 25 th, 75 th ); MITT population
15 Co-Primary outcome: 30-day all-cause mortality or HF rehospitalization 12 P=0.31 Hazard Ratio 0.93 (95% CI: 0.8,1.08) Placebo 8 Nesiritide % day Death/HF Rehospitalization 30-day Death HF Rehospitalization Risk Diff (95 % CI) -0.7 (-2.1; 0.7) -0.4 (-1.3; 0.5) -0.1 (-1.2; 1.0)
16 30 day death/hf readmission subgroups All Subjects N=6836 Baseline SBP (mmhg) Baseline Ejection Fraction (%) Renal function- MDRD GFR (ml/min/m 2 ) History of CAD History of Diabetes Mellitus < <40 40 <60 60 No Yes No Yes N=3346 N=3490 N=4362 N=1187 N=3395 N=3093 N=3092 N=3742 N=3923 N= Risk Difference <0: Favors Nesiritide; Risk Difference >0: Favors Placebo Difference (%) and 95% Confidence Interval
17 30 day death/hf readmission subgroups All Subjects N=6836 Inotrope Use at Randomization Vasodilators Diuretics Study Drug Bolus Time from Hosp to Rand (hrs) No Yes None Any IV Vasodilators No IV Nitroglycerin IV Nitroglycerin No Yes No Yes < N=6556 N=280 N=5889 N=942 N=5943 N=892 N=691 N=6145 N=2609 N=4227 N=3426 N= Risk Difference <0: Favors Nesiritide; Risk Difference >0: Favors Placebo Difference (%) and 95% Confidence Interval
18 % Subjects % Subjects Co-Primary Endpoint: 6 and 24 hour dyspnea 6 Hours 24 Hours P= % 44.5% % P= % Placebo 3371 Nesiritide Placebo 3416 Nesiritide Markedly Better Moderately Better Minimally Better No Change Minimally Worse Moderately Worse Markedly Worse
19 Dyspnea at 6 and 24 Hours Odds for Marked-Moderate Improvement 6 hours 24 hours All Subjects N=6860 N=6769 SBP < N=3369 N=3491 N=3314 N=3455 GFR <60 60 N=3494 N=3121 N=3349 N=3075 Ejection Fraction <40 40 N=4385 N=1186 N=4335 N=1171 CAD No Yes N=3115 N=3743 N=3082 N=3685 Diabetes No Yes N=3930 N=2930 N=3887 N= OR <1: Favors Placebo; OR >1: Favors Nesiritide; Odds Ratio of Markedly/Moderately vs. Other
20 Dyspnea at 6 and 24 Hours Odds for Marked-Moderate Improvement 6 hours 24 hours All Subjects N=6860 N=6769 Inotropes No Yes N=6574 N=286 N=6481 N=288 Vasodilators None Any IV Vaso No IV Nitro IV Nitro N=5912 N=943 N=5965 N=894 N=5835 N=929 N=5886 N=882 Diuretics No Yes N=691 N=6169 N=679 N=6090 Study Medication Bolus Time from Hosp to Rand No Yes < N=2612 N=4248 N=3428 N=3432 OR <1: Favors Placebo; OR >1: Favors Nesiritide; Odds Ratio of Markedly/Moderately vs. Other N=2564 N=4205 N=3369 N=3400
21 Secondary endpoints Placebo (n=3511) Nesiritide (n=3496) Difference (95% CI) P- value Persistent or worsening HF or all-cause mortality through discharge 4.8% (165) 4.2% (147) -0.5 (-1.5 to 0.5) 0.30 Days alive and outside of hospital through Day (-0.13 to 0.53) 0.16 CV death or CV rehosp through Day % (402) 10.9% (372) -0.9 (-2.4 to 0.6) 0.24 Placebo (n=3511) Nesiritide (n=3496) P-value Well Being at 6 hours* 40.3% 41.4% 0.32 Well Being at 24 hours* 63.7% 65.7% 0.02 *Combined response for moderately/markedly better
22 Cum Dist Cum Dist Renal Safety Anytime Through Day 30 Placebo (n=3509) Nesiritide (n=3498) P-value >25% decrease egfr 29.5% 31.4% 0.11 Placebo Nesiritide End of Treatment Creatinine Discharge or 10 day Creatinine Creatinine (mg/dl) Creatinine (mg/dl)
23 Hypotension Placebo (n=3509) Nesiritide (n=3498) Risk Difference (95% CI) P- value Any hypotension (Through Day 10/discharge) 15.3% (538) 26.6% (930) 11.3 (9.4 to 13.1) <.001 Asymptomatic Hypotension 12.4% (436) 21.4% (748) 9.0 (7.2 to 10.7) <.001 Symptomatic Hypotension 4.0% (141) 7.1% (250) 3.1 (2.1 to 4.2) <.001
24 30-day mortality meta-analysis Odds Ratio (95% CI) Mills (N=163) 0.38 (0.05, 2.74) Efficacy (N=127) 1.24 (0.23, 6.59) Comparative (N=175) 1.43 (0.50, 4.09) PRECEDENT (N=147) 0.59 (0.18, 2.01) VMAC (N=498) 1.63 (0.77, 3.44) PROACTION (N=237) 6.93 (0.89, 53.91) COMBINED 30 day w/out ASCEND 1.28 (0.73, 2.25) ASCEND-HF (N=7007) 0.89 (0.69, 1.14) COMBINED with ASCEND 1.00 (0.76, 1.30)
25 Conclusions Nesiritide did not reduce the rate of recurrent heart failure hospitalization or death at 30 days. Nesiritide reduced dyspnea to a modest degree, consistent with previous findings but did not meet prespecified protocol criteria for statistical significance at 6 and 24 hours. Nesiritide did not affect 30-day all cause mortality nor did it worsen renal function as had been suggested by prior meta-analyses of smaller studies.
26 Implications Nesiritide can now be considered a safe therapy in patients with acute heart failure. Further analysis of ASCEND-HF is likely to permit better understanding of acute heart failure and patient profiles that may potentially benefit from nesiritide. Our results from this large randomized trial emphasize both the challenges of making therapeutic decisions on inadequate evidence as well as the urgent need for large, well-conducted trials capable of informing clinical practice
27 Steering Committee North America: Kirkwood F. Adams Jr MD; Javed Butler, MD;Maria Rosa Costanzo, MD; Mark E. Dunlap, MD; Justin A. Ezekowitz, MBBCh, MSc; David Feldman, MD, PhD; Gregg C. Fonarow, MD; Stephen S. Gottlieb, MD, MHS; James A. Hill, MD, MS; Judd E. Hollander, MD; Jonathan G. Howlett, MD; Michael Hudson, MD; Mariell L. Jessup, MD; Serge Lepage, MD; Wayne C. Levy, MD; Naveen Pereira, MD; W.H. Wilson Tang, MD; John R. Teerlink, MD; David J. Whellan, MD; Clyde W. Yancy, MD Europe: Stefan D. Anker, MD, PhD; Dan Atar, MD; Alexander Battler, MD; Ulf Dahlstrom, MD, PhD; Aleksandras Laucevicius, MD; Marco Metra, MD; Alexander Parkhomenko, MD; Piotr Ponikowski, MD, PhD; Jindrich Spinar, MD; Svetla Torbova, MD; Filippos Triposkiadis, MD;Vyacheslav Mareev, MD; Adriaan A. Voors, MD, PhD; Faiez Zannad, MD, PhD Latin America: Rodrigo Botero, MD; Nadine Clausell, MD; Ramón Corbalán, MD; Rafael Diaz, MD; Gustavo Méndez Machedo Asia Pacific: Ping Chai, MD; Wen-Jone Chen, MD; Henry Krum, MBBS, PhD; Sanjay Mittal, MD; Byung Hee Oh, MD; Supachai Tanomsup, MD; Richard W. Troughton, MD, PhD; YueJin Yang, MD;
28 BACKUP SLIDES
29 Subgroups: Bolus and IV NTG Odds for Marked/Moderate Improvement (95% CI) 6 Hours Without Bolus 1.06 (0.90, 1.23) With Bolus 1.14 (1.01, 1.28) Without IV NTG 1.12 (1.01, 1.24) With IV NTG 1.02 (0.78, 1.33) 24 Hours Without Bolus 1.07 (0.91, 1.26) With Bolus 1.12 (0.98, 1.27) Without IV NTG 1.12 (1.01, 1.25) With IV NTG 0.96 (0.71, 1.28)
30 Blood Pressure Over Time Systolic Blood Pressure
31 Dyspnea (higher is better) EFFECT OF NESIRITIDE IN NAÏVE PATIENTS P = P = Hr 24 Hr Dyspnea Measurement Placebo Nesiritide
32 Relative Odds for Better Status Dyspnea (Higher is Better) Baseline treatment and 6 hour dyspnea relief P=0.04 P= P= None Diuretic only Diuretic & Vasodilator N= Baseline Treatment Placebo Nesiritide
33 Power Post-hoc Power Calculation Relative Risk
34 Relative Odds for Better Status Dyspnea (Higher is Better) Overall effect of time from presentation to study drug on 6 hour dyspnea relief P=< to 4 4 to 8 8 to to to to to to 36 >36 N= Time to Drug (hours)
35 Relative Odds for Better Status Dyspnea (Higher is Better) Estimate of effect of nesiritide on 6 hour dyspnea relief based on time from presentation to study drug Time to Drug Placebo Nesiritide Placebo Nesiritide Mean (pts) Mean (pts) Chi-square for treatment = 9.66 for 2 d.o.f., p =
36 Blood Pressure Over Time Placebo Nesiritide Systolic Blood Pressure (mmhg) Baseline 3 hrs 24 hrs End Rx D/C
Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials
Mortality as an Efficacy or Safety Endpoint : Lessons Learned from the Heart Failure Trials Christopher M. O Connor, MD Professor of Medicine Director, Duke Heart Center Acting Chief, Division of Cardiology
More informationRenal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial
Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Background AHF + Renal
More informationMihai Gheorghiade MD
Mihai Gheorghiade MD Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois On behalf of: Stephen J Greene MD; Javed Butler MD MPH MBA; Gerasimos Filippatos
More informationBuilding Quality into Clinical Development: ASCEND-HF as a Case Example. Adrian Hernandez, MD and Craig Reist, PhD
Building Quality into Clinical Development: ASCEND-HF as a Case Example Adrian Hernandez, MD and Craig Reist, PhD Acute Heart Failure: Overlooked Acute HF Acute MI Hospitalizations/year 1,000,000 1,000,000
More informationEffect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF)
Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF) Piotr Ponikowski, Dirk J. van Veldhuisen, Josep Comin-Colet Georg Ertl, Michel Komajda,
More informationEffect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial
Effect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial Aldo P. Maggioni, MD, FESC Associazione Nazionale Medici
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationHow to define the target population?
Heart Failure 2011 22-24 May. Gothenburg, Sweden Mortality or morbidity as target in acute heart failure trials How to define the target population? Marco Metra, Brescia The Burden of Acute HF Acute HF
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationEffect of Nesiritide in Patients with Acute Decompensated Heart Failure
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Effect of in Patients with Acute Decompensated Heart Failure C.M. O Connor, R.C. Starling, A.F. Hernandez, P.W. Armstrong, K. Dickstein,
More informationImpact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction
Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationManagement of Acute Heart Failure
Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.
More informationDisclosure Information : No conflict of interest
Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure : a randomized, controlled trial M. Shigekiyo, K. Harada, A. Okada, N.
More information2013 ACCF/AHA Guideline for the Management of Heart Failure COPYRIGHT
2013 ACCF/AHA Guideline for the Management of Heart Failure by Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E. Casey, Mark H. Drazner, Gregg C. Fonarow, Stephen A. Geraci, Tamara
More informationAHA Nov 18, 2013 Late Breaking Session
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2013 Late Breaking Session Marc A. Pfeffer MD, PhD, on behalf of the TOPCAT Investigators TOPCAT
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationTreatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials
Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,
More informationACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014
ACUTE HEART FAILURE Julie Gorchynski MD, MSc, FACEP, FAAEM Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 No disclosures Objectives Overview Cases Current Therapy
More informationSerelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure
Serelaxin: insights into its haemodynamic, biochemical, and clinical effects in acute heart failure Item Type info:eu-repo/semantics/article Authors Hernández, Adrian V. Citation Eur Heart J (2014) 35
More informationLearning Objectives. A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials. Fidaxomicin vs. Vancomycin. Outline 1/3/2012
Learning Objectives A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials Amy E. Lodolce, PharmD, BCPS Assistant Director, Drug Information Group UIC College of Pharmacy Describe the methods and
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationNesiritide: Harmful or Harmless?
Nesiritide: Harmful or Harmless? Michael P. Dorsch, Pharm.D., and Jo Ellen Rodgers, Pharm.D. Nesiritide is the recombinant form of human B-type (brain) natriuretic peptide (BNP), and its amino acid sequence
More informationChristopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University Editor
New Strategies in the Management of Acute and Advanced Heart Failure Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine (adj.) Duke University
More informationNatriuretic Peptide Guided Therapy for Heart Failure
Natriuretic Peptide Guided Therapy for Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Duke Clinical Research Institute Disclosures Research Grants
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationCONGESTIVE HEART FAILURE
CONGESTIVE HEART FAILURE ACOI IM BOARD REVIEW 2018 MARTIN C. BURKE, DO, FACOI DISCLOSURES I AM PRINCIPAL INVESTIGATOR AND RECEIVE GRANTS FOR HEART FAILURE TRIALS FROM BOSTON SCIENTIFIC, MEDTRONIC AND ST
More informationStopping the Revolving Door of ADHF
Stopping the Revolving Door of ADHF Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationCardio-Renal Syndrome in Acute Heart Failure:
Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine
More informationEffect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (TRUE-AHF)
Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (TRUE-AHF) Elizabeth Tien, PharmD, BCPS PGY2 Cardiology Pharmacy Resident Moses H. Cone Memorial Hospital Greensboro, NC Kristen Pogue,
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationHospitalization for acute heart failure is common and is
In-Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization Adam D. DeVore, MD; Bradley G. Hammill, MS; Puza P. Sharma, MBBS, MPH, PhD; Laura G. Qualls,
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationAcute heart Failure. Critical cardiac care: update Markku S. Nieminen Helsinki, Finland. M S Nieminen, AHF ,ESC Stockholm
Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen Helsinki, Finland M S Nieminen, AHF 300810,ESC Stockholm Acute heart Failure Critical cardiac care: update 2010 Markku S. Nieminen
More informationPravin Manga Division of Cardiology Department of Medicine University of Witwatersrand
Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical
More informationAtrial fibrillation (AF) is the most common chronic cardiac
Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial Seraj Abualnaja, MD; Mohua Podder, PhD;
More informationTHE ROLE OF NESIRITIDE IN THE MANAGEMENT OF ACUTE DECOMPENSATED HEART FAILURE: REVIEW OF MORTALITY DATA AND RECOMMENDATIONS FOR CLINICAL USE
THE ROLE OF NESIRITIDE IN THE MANAGEMENT OF ACUTE DECOMPENSATED HEART FAILURE: REVIEW OF MORTALITY DATA AND RECOMMENDATIONS FOR CLINICAL USE J. Douglas Kirk MD, FACEP Department of Emergency Medicine,
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationNatriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA
Natriuretic Peptides The Cardiologists View Christopher defilippi, MD University of Maryland Baltimore, MD, USA Disclosures Research support: Alere, BG Medicine, Critical Diagnostics, Roche Diagnostics,
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More informationLoop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF
European Journal of Heart Failure (2015) 17, 340 346 doi:10.1002/ejhf.235 Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF Adam D. DeVore 1,2 *, Vic Hasselblad
More informationIntegrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure
Integrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure J. Herbert Patterson, Pharm.D., FCCP One of Four Continuing Education Programs in the Series, Acute Decompensated
More informationSystolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine
Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Donna Mancini MD Choudhrie Professor of Cardiology Columbia University Speaker Disclosure Amgen
More informationAngiotensin Neprilysin Inhibition in Acute Decompensated Heart Failure
Original Article Angiotensin Neprilysin Inhibition in Acute Decompensated Heart Failure Eric J. Velazquez, M.D., David A. Morrow, M.D., M.P.H., Adam D. DeVore, M.D., M.H.S., Carol I. Duffy, D.O., Andrew
More informationManagement of Advanced Systolic Heart Failure. Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University
Management of Advanced Systolic Heart Failure Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University American College of Cardiology Foundation (ACCF) American Heart Association
More informationMihai Gheorghiade, MD Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois
Effect of Aliskiren on Post-discharge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure: AliSkiren TRial ON Acute heart failure outcomes (ASTRONAUT) Mihai Gheorghiade,
More informationA Phase 2 Study of Intravenous Omecamtiv Mecarbil, A Novel Cardiac Myosin Activator, In Patients With Acute Heart Failure
A Phase 2 Study of Intravenous Omecamtiv Mecarbil, A Novel Cardiac Myosin Activator, In Patients With Acute Heart Failure John R. Teerlink, G. Michael Felker, John J. V. McMurray, Piotr Ponikowski, Marco
More informationSacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP
Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest
More informationReassessing treatment of acute heart failure syndromes: the ADHERE Registry
European Heart Journal Supplements (2005) 7 (Supplement B), B13 B19 doi:10.1093/eurheartj/sui008 Reassessing treatment of acute heart failure syndromes: the ADHERE Registry Mihai Gheorghiade 1 * and Gerasimos
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationNitrate s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT) A Randomized Clinical Trial
Nitrate s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT) A Randomized Clinical Trial Margaret M Redfield On behalf of the NHLBI Heart Failure Clinical Research Network
More informationROSE-AHF and Beyond. Gerasimos Filippatos, FESC, FHFA President Heart Failure Association
ROSE-AHF and Beyond Gerasimos Filippatos, FESC, FHFA President Heart Failure Association From: Braunwald s Heart Disease. 9th ed. Philadelphia, Elsevier, 2011 Determinants and forms of worsening renal
More informationPALLAS. Dronedarone on Top of Standard Therapy. Stuart J. Connolly MD. on behalf of the PALLAS investigators
PALLAS Permanent Atrial FibriLLAtion Outcome Study using on Top of Standard Therapy Stuart J. Connolly MD on behalf of the PALLAS investigators http://clinicaltrials.gov Number: NCT01151137 1 Disclosure
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationAmbarish Pandey, MD UT Southwestern Medical Center Dallas,
Hospital Performance Based on 30-Day Risk Standardized Mortality and Long-Term Survival after Heart Failure Hospitalization An Analysis of the GWTG-HF Registry Ambarish Pandey, MD UT Southwestern Medical
More informationIn the acute care setting, dyspnea is the most commonly
Hemodynamic Determinants of Dyspnea Improvement in Acute Decompensated Heart Failure Amir Solomonica, MD, MPH; Andrew J. Burger, MD; Doron Aronson, MD Background Dyspnea relief constitutes a major treatment
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationState of the Art: acute heart failure Is it just congestion?
ESC CONGRESS 2017 Barcelona, 26. 30. August 2017 State of the Art: acute heart failure Is it just congestion? S.B. Felix, FESC Klinik für Innere Medizin B Ernst-Moritz-Arndt-Universität Greifswald 1456
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationTips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance
Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance J. Parissis Attikon University Hospital, Athens, Greece Disclosures ALARM investigator received
More informationUniversity of Groningen. Diuretic response and renal function in heart failure ter Maaten, Jozine Magdalena
University of Groningen Diuretic response and renal function in heart failure ter Maaten, Jozine Magdalena IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationOriginal Article. Representativeness of RELAX-AHF Clinical Trial Population in Acute Heart Failure
Original Article Representativeness of RELAX-AHF Clinical Trial Population in Acute Heart Failure Teresa S. Wang, BS; Anne S. Hellkamp, MS; Chetan B. Patel, MD; Justin A. Ezekowitz, MBBCh, MSc; Gregg C.
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationPrevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Marc S. Sabatine, MD, MPH on behalf of the PEGASUS-TIMI 54 Executive
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationHYPERTENSION: UPDATE 2018
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
More informationCURRICULUM VITAE MARCO METRA, M.D. I. Personal Citizenship status Italian Birthdate September 13th, 1957
CURRICULUM VITAE MARCO METRA, M.D. I. Personal Citizenship status Italian Birthdate September 13th, 1957 Birthplace Parma, Italy Marital status Married, 3 children Mailing address Cardiology The Department
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationUltrafiltration in Decompensated Heart Failure. Description
Subject: Ultrafiltration in Decompensated Heart Failure Page: 1 of 7 Last Review Status/Date: September 2016 Ultrafiltration in Decompensated Heart Failure Description Ultrafiltration is a technique being
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationClinical Investigations
Clinical Investigations Nesiritide in Acute Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials Address for correspondence: William T. Abraham, MD 473 West 12th Avenue, Suite
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationPost Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
More informationSelective Cardiac Myosin Activators in Heart Failure
Selective Cardiac Myosin Activators in Heart Failure John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationAcute heart failure syndromes: clinical challenges. Pathophysiology. ESC Congress August. Paris, France. Marco Metra
ESC Congress 2011 27-31 August. Paris, France. Acute heart failure syndromes: clinical challenges. Pathophysiology Marco Metra Cardiology, Dept. Of experimental and applied medicine. University of Brescia.
More informationTroponin I in acute decompensated heart failure: insights from the ASCEND-HF study
European Journal of Heart Failure Advance Access published July 4, 2012 European Journal of Heart Failure doi:10.1093/eurjhf/hfs110 Troponin I in acute decompensated heart failure: insights from the ASCEND-HF
More informationMedical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More informationPrognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure
Cleveland State University EngagedScholarship@CSU Mathematics Faculty Publications Mathematics Department 1-1-2016 Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects
More informationHeart Failure: Guiding-therapy
Heart Failure: Guiding-therapy Justin A. Ezekowitz, MBBCh MSc FRCPC FACC FESC FAHA Associate Professor, University of Alberta Co-Director, Canadian VIGOUR Centre Cardiologist, Mazankowski Alberta Heart
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationKnown Actions of Digoxin
Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (
More informationHF-PEF: Symptoms, quality of life and mortality/morbidity
HF-PEF: Symptoms, quality of life and mortality/morbidity May 21, 2011 John McMurray, MD Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham & Women s Hospital Boston; Visiting Professor of Medicine,
More informationManagement of acute decompensated heart failure and cardiogenic shock. Arintaya Phrommintikul Department of Medicine CMU
Management of acute decompensated heart failure and cardiogenic shock Arintaya Phrommintikul Department of Medicine CMU Acute heart failure: spectrum Case 64 y/o M with Hx of non-ischemic DCM (LVEF=25-30%)
More informationIN-HF on line: patient settings (Enrollement period= )
IN-HF on line: atient settings (Enrollement eriod= 1995-2018) N of centers (total) 187 N of centers (ts. AHF only) 13 N of centers (ts. CHF only) 71 N of centers (both ts. AHF and CHF) 103 N of atients
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationReducing Hospital Readmissions and Increasing Time to Hospital Readmission in Blacks with Heart Failure
10th Annual National Summit on Health Disparities CBC Health Braintrust Meeting April 22 April 23, 2013, Washington, DC Reducing Hospital Readmissions and Increasing Time to Hospital Readmission in Blacks
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationProduct: Omecamtiv Mecarbil Clinical Study Report: Date: 02 April 2014 Page 1
Date: 02 April 2014 Page 1. 2. SYNOPSIS Name of Sponsor: Amgen Inc. Name of Finished Product: Omecamtiv mecarbil injection Name of Active Ingredient: Omecamtiv mecarbil (AMG 423) Title of Study: A double-blind,
More informationPractical Points in Cardiorenal Syndrome
Practical Points in Cardiorenal Syndrome Vichai Senthong, MD. Cardiovascular Unit, Faculty of Medicine Khon Kaen university HFCT Annual Scientific Meeting June 16, 2017, Eastin Grand Sathorn Hotel, Bangkok
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationNew Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition
New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition Prakash Deedwania, MD, FACC, FACP, FCCP, FAHA Professor of Medicine, UCSF School of Medicine, Director,
More informationREVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Martin Landray and Louise Bowman on behalf of the HPS 3 / TIMI 55 - REVEAL Collaborative
More information